Dahua Jixian published a report. Alibaba Health's revenue for the 2024 fiscal year is expected to drop 5% year-on-year, adjusted profit will increase by 30% year-on-year, and the revenue and profit targets for fiscal year 2025 are 15% and 70% year-on-year growth, respectively. As business expansion was slower than expected, the bank lowered Ali Health's revenue growth forecast for the 2024 and 2025 fiscal years from 14% and 21% to -5% and 15%, respectively, but with the synergy between steady demand for healthcare products and Ali Mama's marketing business, it remains optimistic about its long-term growth prospects. Dahua Jixian maintained Ali Health's “buy” rating, and the target price was lowered from HK$6 to HK$4.